- Nanosphere (NASDAQ:NSPH) released preliminary revenue results for the second quarter of 2012 at $1.3 million vs. analyst expectations of $1.5 million. Sales were up 160% … Continue Reading
Read now- Alnylam (NASDAQ: ALNY) reported positive Phase I proof-of-concept and safety results for ALN-TTR02, the company’s most advanced wholly-owned compound. ALN-TTR02 is being developed to treat Transthyretin-Mediated … Continue Reading
Read now- Continuing its upward trend from yesterday, Peregrine Pharmaceuticals (NASDAQ:PPHM) broke above $1.00 on a 12% gap up this morning and has nearly doubled in the … Continue Reading
Read now- Acadia Pharmaceuticals (NASDAQ:ACAD) is down in pre-market trading after reporting this morning that they and their partner Meiji Seika are discontinuing development of schizophrenia treatment … Continue Reading
Read now- Ampio Pharmaceuticals (NASDAQ:AMPE) announced this morning that it has priced its 4.6M share equity offering at $3.25 per share ,with Aegis Capital Corp. and Fordham … Continue Reading
Read nowResearch - PREVIEW: The Prescription Drug User Fee Act (PDUFA) or FDA ‘Action’ date for Vivus’ (NASDAQ:VVUS) obesity drug, Qnexa, is July 17th – an event that’s … Continue Reading
Read now- Affymax, Inc. (AFFY) gapped up 10% this morning with the announcement of a major supply agreement between Takeda Pharmaceuticals (TKPYY), Affymax, and Fresenius Medical Care … Continue Reading
Read now